What’s YOUR health score? We know health systems aren’t quite there yet, but Sir Peter Donnelly CEO and Co-Founder of Genomics plc believes that because of recent advances in genetic risk testing, in the future individuals might have health scores for various diseases and conditions that can help them live longer, healthier lives. Watch the full roundtable about how our Polygenic Risk Scoring can and will impact the future of healthcare and life insurance: https://lnkd.in/ex7jyWKm
Genomics plc
Biotechnology Research
Oxford, Oxfordshire 9,935 followers
Transforming health, healthcare and drug discovery through the power of genomics
About us
We are a pioneering healthcare company that aims to transform health through the power of genomics. The company was formed in 2014 by four world-leading statistical and human geneticists at the University of Oxford, including Professor Sir Peter Donnelly and Professor Gil McVean. We use large-scale genetic information to realise preventative medicine and improve drug discovery. We're a world-leader in genomic prevention: a paradigm-changing approach to sustainable healthcare which for the first time allows reliable, personalized estimates of risk for all the common diseases and cancers, well ahead of disease manifestation, allowing accurate and early interventions and tailored screening. Our proprietary algorithms and databases offer something no competitor can: the ability to accurately link minute variation across the entire genome to changes in thousands of biological measurements and disease outcomes, to generate population-level insights for healthcare systems, individual-level insights for clinicians about the risk of common diseases, and new understanding of disease processes. In August 2018, we announced a multi-year collaboration with Vertex to use human genetics and data science to advance discovery of precision medicines. We also has several pilot programmes in development within UK and US healthcare systems. Our team is a multi-disciplinary group focused on finding powerful and creative solutions for bringing subject-leading science to as wide an audience as possible, and, in doing so, offer the chance of transforming lives around the world. The workforce is highly qualified and consists of over 90 people, including genomic scientists, computational biologists, statisticians, software engineers, product developers, data scientists and commercial strategists. We are headquartered in Oxford, with offices in Cambridge (UK) and Boston (US).
- Website
-
http://www.genomicsplc.com/
External link for Genomics plc
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Oxford, Oxfordshire
- Type
- Public Company
- Founded
- 2014
- Specialties
- genomics, machine learning, drug discovery, and Precision Health
Locations
-
Primary
Get directions
King Charles House
Park End Street
Oxford, Oxfordshire OX1 1JD, GB
-
Get directions
50-60 Station Road
Cambridge, England CB1 2JH, GB
-
Get directions
Boston, Massachusetts , US
Employees at Genomics plc
Updates
-
We're thrilled to announce that our Integrated Risk Tool for cardiovascular disease has received another major validation! This groundbreaking research, led by the University of Leicester and published today in the prestigious European Heart Journal, highlights the huge potential to revolutionize early prevention. Our risk tool combines a polygenic risk score with a standard risk assessment tool, producing incredible results with a 12% overall increase in the number of future cases being flagged as high risk, and an impressive 48% increase for individuals aged 40-54! More people being identified means earlier and more effective preventive action, helping more people live healthier, longer lives. Stay tuned as we continue to innovate and make strides in cardiovascular health! #HealthInnovation #ForHealthForLife https://lnkd.in/eACrcC-A
-
How can genetic testing help to include more diverse participants in clinical trials and studies for drug discovery and biopharma? Sir Peter Donnelly CEO and Co-Founder of Genomics plc, answers this question and many more about our Polygenic Risk Scoring during this roundtable about how Genomics can enable individuals to live longer, healthier lives: https://lnkd.in/eQEhW-wf
-
The old motto of Life Insurance companies was “if a death happens, we’ll be there for you.” Now, with Polygenic Risk Scoring, Marc Giguere, President and CEO of Munich Re Life US, hopes to update that phrase to, “We’ll be there when you need us, but what if we can help you live a longer, healthier, better life?” Watch the full roundtable about how Genomics plc's Polygenic Risk Scoring can enable policyholders to live longer, healthier lives here: https://lnkd.in/ex7jyWKm #ForHealthForLife #innovation
-
Last week, we hosted our first Learning at Work Week, to empower and inspire our team members through learning and development. Thank you to everyone who participated and contributed, including our external speakers (Spinach, Blinkist & Ross Stevenson) and Genomics team members who shared their expertise. Here's to more opportunities for growth and development together 🚀
-
“The mindset around genetic risk testing has changed for life insurance policyholders. They want access to that technology so that they can live longer, healthier lives,” according to Sears Merritt, Head of Enterprise + Technology for MassMutual. Watch the full roundtable about how Genomics plc's Polygenic Risk Scoring can enable policyholders to live longer, healthier lives here: https://lnkd.in/ex7jyWKm #innovation #ForHealthForLife
-
With our industry-leading polygenic risk identification platform, we can move to a world that is more personalized and tailored to an individual’s health needs. Watch the full roundtable about how Genomics plc's genetic risk scoring can enable policyholders to live longer, healthier lives here: https://lnkd.in/ex7jyWKm
-
Thank you Jasmine Pennic for featuring the news of our latest partnership announcement with GSK in HIT Consultant Media. To learn more about our collaboration and the exciting news, check out the story here: https://lnkd.in/dBNGAmWR #clinicaltrials #coveragewin #ForHealthForLife
Genomics plc & GSK Partner to Optimize Clinical Trials with Genetic Risk Testing
hitconsultant.net
-
🚀 Breaking News! 🚀 Genomics plc and GSK have joined forces to transform clinical trial design with the power of genomics. Our partnership will evaluate how polygenic risk scores (PRS) can be used in clinical trials to enhance patient selection and trial efficiency. 🧬 Through the utilisation of PRS-based methodologies, we aim to optimise trial design, reducing both participant numbers and study durations while improving outcomes. Discover how we’re shaping the future of precision medicine. https://lnkd.in/et_exuHG #Genomics #PrecisionMedicine #ClinicalTrials #Innovation #ForHealthForLife
Genomics plc and GSK establish precision medicine collaboration to assess polygenic risk scores in clinical trial design
prnewswire.com
-
⏰ Don’t miss out! ⏰ There’s still time to register for the “Leveraging Genetic Risk Testing for Healthier, Longer Lives: Exploring Insurance Perspectives” webinar TOMORROW, Wednesday at 2PM EST. Our CEO and Co-Founder Peter Donnelly will be discussing genetic offerings from the life insurance perspective at this event hosted by Digital Health Institute for Transformation (DHIT). You’ll have the opportunity to hear from industry thought leaders including Marc Giguere of Munich Re, Sears Merritt of MassMutual and Cindy Hallberlin of DHIT. They’ll delve into the intersection of genetic offerings and insurance practices, exploring the potential benefits, privacy considerations, and practical implications of this evolving trend. Click here to register for this free and informative webinar: https://lnkd.in/e4aUkWX9 #genomics #lifeinsurance #innovation #insurance #genetics #digitalhealth #webinar #forhealthforlife
Digital Health Virtual Roundtable: Leveraging Genetic Risk Testing
eventbrite.com